ACTU - צמיחת רווחי EPS רבעונית Actuate Therapeutics

Actuate Therapeutics, Inc. (ACTU) is currently expanding the clinical presence of its therapeutic systems. The quarterly EPS growth rate demonstrates a volatile vector, with the latest value recorded as 43.40. The company is developing unique GSK-3 inhibitors to combat cancer, leveraging bioengineering. However, a lack of profitability and reliance on external financing render its cash flows unpredictable.
Actuate Therapeutics - פילוחים אנליטיים ומדדי מפתח (ACTU)

Defensive assets are selected based on their ability to generate profit amid market volatility. Actuate Therapeutics, Inc. (ACTU) seeks this resilience through the expansion of elraglusib and the development of its oncology pipeline. The metric measures the rate of change in earnings per share to assess the business's margin of safety. By analyzing the shift in quarterly EPS levels, an investor identifies the moment financial momentum fades. A slowdown in this growth signals risks before a crisis occurs.